HCPCS code J3110 – Injection, teriparatide

Found our content helpful?

Key takeaways

HCPCS code J3110 describes injection of teriparatide at 10 mcg per unit. It is used for Medicare and Medicaid billing of Forteo and Bonsity under buy-and-bill.

The standard daily dose of 20 mcg equals 2 units of J3110 per administration, so billing quantity must match administration records exactly.

Medicare Part B reimburses J3110 at ASP plus 6% for physician-administered injections. Rates update quarterly, so check the current CMS ASP file before billing.

Modifier JZ became mandatory on July 1, 2023, and claims carrying neither JW nor JZ have been subject to rejection since October 1, 2023.

Practice management software like Pabau flags a unit mismatch, prompts for JW or JZ, and tracks prior authorization before the claim goes out.

Teriparatide: Drug overview and clinical context

Teriparatide is a recombinant parathyroid hormone (PTH) analogue. Bisphosphonates slow bone resorption, while teriparatide stimulates osteoblast activity to increase bone formation. The FDA has approved it for adults at high risk of fracture, and the label names three groups:

• Postmenopausal women with osteoporosis
• Men with primary or hypogonadal osteoporosis
• Patients with glucocorticoid-induced osteoporosis

Two products use HCPCS code J3110. Forteo, manufactured by Eli Lilly, is the original brand. Bonsity is a 505(b)(2) version of Forteo, approved as a therapeutic equivalent rather than a licensed biosimilar.

The distinction matters when a payer policy names biosimilars specifically. Teriparatide is a small molecule that clears the FDA on the drug pathway, so Bonsity holds an NDA rather than a biologics license. Both products share the same J-code, so payers tell them apart by the National Drug Code (NDC) on the claim.

J3110 billing unit and dosing

Each unit of J3110 represents 10 mcg of teriparatide. The FDA-approved standard daily dose is 20 mcg, administered subcutaneously once daily. This means practices bill 2 units of J3110 per standard administration.

Billing quantity must match what was administered and documented in the patient record. Over-billing units relative to the administered dose is a common audit trigger for buy-and-bill injectable claims.

Medicare reimbursement and fee schedule for HCPCS code J3110

Medicare Part B reimburses HCPCS code J3110 under the buy-and-bill model at the Average Sales Price (ASP) plus 6%. This formula is standard for Part B physician-administered drugs, covering the practice’s acquisition cost plus a handling margin. ASP rates update quarterly. Verify the current rate against the CMS Physician Fee Schedule lookup before billing, because an older figure will not reflect current payment.

Those quarterly updates decide the cash flow on every buy-and-bill purchase. A rate change mid-quarter can squeeze the margin when a practice has already bought inventory at the prior ASP.

Reconciliation follows the same calendar. Medicare’s remittance advice reflects the J3110 payment at the rate for the date of service, not the billing date. Reconcile against the quarter in which the service was rendered.

Buy and bill process for teriparatide

Under buy-and-bill, the practice buys teriparatide from a specialty pharmacy or distributor and stores it on site. Staff administer it to the patient, then bill J3110 to Medicare or the patient’s insurer.

Medicare Part D works differently. The patient collects the drug from a retail pharmacy, so the practice carries no acquisition cost and no inventory risk.

Most buy-and-bill denials on injectable drugs come down to paperwork. A claim goes out with no proof of acquisition on file, or it bills more units than the practice purchased. Either one becomes a recoverable overpayment once a payer audits the record.

1. Acquire the drug: Purchase teriparatide (Forteo or Bonsity) from a licensed specialty pharmacy or wholesaler. Retain the invoice and lot number for documentation.
2. Store correctly: Teriparatide requires refrigeration (2-8°C). Document the storage log to demonstrate integrity of the drug on the date of administration.
3. Administer and document: Inject subcutaneously per the prescribing information. Record the dose, units, site, lot number, and administering clinician in the patient chart.
4. Record wastage: If any drug from a single-use container is discarded, document the amount for JW modifier reporting. Use the JZ modifier when no drug was wasted.
5. Submit the claim: Bill J3110 with the correct unit count, applicable modifiers, NDC number, and paired ICD-10 diagnosis code. Include the administration code (96372) on the same claim.

Teriparatide is billed under Part B when a clinician administers it in the office. If the patient self-administers at home, Part D usually covers the drug through the pharmacy benefit, and J3110 does not apply.

ICD-10 diagnosis codes for J3110 billing

Every J3110 claim requires a paired ICD-10-CM diagnosis code that establishes medical necessity. Teriparatide is indicated for osteoporosis with high fracture risk, so the relevant codes sit in the M80 and M81 series. Payers may deny a claim where the diagnosis does not justify teriparatide over first-line bisphosphonate therapy.

Select the most specific code available, and include the encounter qualifier on fracture claims (initial, subsequent, sequela). Full descriptions and encounter characters for each of these sit in the ICD-10 code library. Code M81.0 is the most frequently paired diagnosis on teriparatide claims started for high fracture risk without an acute fracture.

Modifiers and place of service for J3110

Modifiers directly affect payment and audit risk for J3110 claims. Using the wrong modifier, or omitting a required one, is among the fastest paths to a denial or a post-payment audit.

CMS phased the waste modifiers in over three dates, which still catches practices out. JZ was optional from January 1, 2023, then became mandatory on July 1, 2023. Claims for single-dose container drugs carrying neither JW nor JZ have been subject to rejection since October 1, 2023.

Document the container size, the amount administered, and any discarded amount in the patient record. That record is what supports the modifier you chose if a payer questions it later.

Place of service: J3110 billed from a physician office uses POS 11. Hospital outpatient settings use POS 22. The POS affects the Medicare payment rate, since the facility fee may be separate in a hospital-based setting.

Prior authorization requirements for J3110

Traditional Medicare fee-for-service does not require prior authorization for J3110. Medicare Advantage plans and commercial payers almost always require it for teriparatide, given its cost next to first-line osteoporosis therapies. Criteria vary by plan year and payer, so treat the list below as illustrative.

• Confirmed osteoporosis diagnosis: DEXA scan T-score at or below -2.5, or documented history of fragility fracture
• Bisphosphonate treatment failure or intolerance: Most payers require documented failure of, or contraindication to, at least one bisphosphonate (alendronate, risedronate, or equivalent)
• High fracture risk documentation: FRAX score or clinical note establishing high absolute fracture risk
• Prescribing physician specialty: Some plans require the prescriber to be an endocrinologist, rheumatologist, or other specialist
• Duration limits: The FDA removed teriparatide’s 2-year lifetime cap and its osteosarcoma boxed warning in November 2020. No hard cap remains on the label, though individual payers may still set their own duration limits

Verifying the patient’s benefits before the first administration confirms whether prior authorization is required and what the payer wants to see. A J3110 claim submitted without a required authorization will deny, and retroactive approval on appeal is never guaranteed.

NDC numbers for teriparatide (Forteo and Bonsity)

CMS requires National Drug Code (NDC) reporting on all Part B drug claims, including J3110. The NDC identifies the product, the manufacturer, and the package size. That lets CMS check whether the billed HCPCS code matches the drug dispensed.

NDC numbers can change when manufacturers update packaging. Source the NDC from the product invoice or the current prescribing information rather than memorizing a number. Format it on the claim in 11-digit format (5-4-2) with no dashes.

By this point every field on the J3110 claim line has a rule attached. Each value also has to agree with a record the practice already holds.

Related HCPCS codes and crosswalk

J3110 does not stand alone on most teriparatide claims. Administration codes and fallback codes appear alongside it, depending on the billing scenario. Knowing which companion code belongs on the claim prevents unbundling errors and missed line items.

Verify the current code description and status against the AAPC HCPCS code lookup before each billing cycle.

How practice management software supports J3110 billing

Reference code sites tell you what J3110 means. They do not help a practice bill it correctly across a high volume of patients. Practice management software like Pabau closes that distance with cleaner claims management at charge entry.

Unit validation is the first check. A coder entering 1 unit when the administered dose needs 2 units gets flagged before submission. The same workflow carries the full J3110 line onto the superbill, including units, modifier, NDC, and the paired ICD-10 code.

• HCPCS code entry with unit validation: Flags quantity mismatches between administered dose and billed units before claim submission
• Modifier prompts: Reminds billing staff to apply JW or JZ based on wastage documentation, reducing the most common J-code claim edits
• Prior authorization tracking: Links authorization status to the claim, preventing J3110 submission without an authorization on file
• NDC field enforcement: Requires NDC entry for Part B drug claims, so CMS compliance is settled at charge entry rather than post-denial
• HIPAA-compliant data handling: Patient and claim records stay inside one audited system across the whole revenue cycle

The practical difference is catching J3110 billing errors at charge entry, before a denial comes back from Medicare or a Medicare Advantage plan.

Book a demo with Pabau to see how the claims workflow handles buy-and-bill injectable drugs in a practice setting.

Streamline your injectable drug billing

Pabau’s claims management tools support HCPCS J-code entry, quantity validation, modifier prompts, and prior authorization tracking. See how it handles buy-and-bill workflows in a live demo.

Book a demo

Conclusion

J3110 itself is a one-line lookup. The work sits in keeping the units, the modifier, the NDC and the diagnosis in agreement with what the chart says.

A practice that settles those four values at charge entry rarely argues about them again. A practice that settles them after a denial pays for the same claim twice, in staff time.

One trade-off is worth remembering. ASP moves every quarter, and inventory bought at last quarter’s price does not move with it. Check the rate before each billing quarter and the buy-and-bill margin holds. Book a demo to see how Pabau keeps a J3110 claim line consistent from the treatment note through to the remittance.

Continue your research

Need guidance on the full medical billing lifecycle? What is medical billing covers the end-to-end billing workflow from charge capture through remittance reconciliation.

Dealing with repeated J-code claim denials? Denial management in healthcare outlines systematic strategies for reducing denial rates on high-cost injectable drug claims.

Want to understand how clearinghouses fit into HCPCS billing? Medical claims clearinghouse guide explains how claims are validated and routed before reaching Medicare and commercial payers.

Frequently asked questions